2023
Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy
Contieri R, Hensley P, Tan W, Grajales V, Bree K, Nogueras-Gonzalez G, Lee B, Navai N, Dinney C, Kamat A. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. European Urology Oncology 2023, 6: 590-596. PMID: 37558542, DOI: 10.1016/j.euo.2023.07.012.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerCancer-specific mortalityBacillus Calmette-GuerinHigh-grade recurrenceHigh-risk non-muscle-invasive bladder cancerOverall survivalBladder cancerEuropean Urological AssociationOncological outcomesNo significant differenceEarly RCPatients treated with bacillus Calmette-GuerinTreated with bacillus Calmette-GuerinNon-muscle invasive bladder cancerIntravesical BCGContemporary cohort of patientsCancer-specific mortality ratesProgression rateBacillus Calmette-Guerin groupEarly radical cystectomyMedian Follow-UpInvasive bladder cancerSignificant differenceCohort of patientsEarly surgical removal
2022
Treatment patterns and health care resource use of patients with metastatic breast cancer with HER2-low expression: A cancer registry-linked insurance claims study.
Check D, Jackson B, Spees L, Dinan M, Kwong J, Mehta S, Wheeler S, Wilson L, Faherty E, Reeder-Hayes K, Lam C. Treatment patterns and health care resource use of patients with metastatic breast cancer with HER2-low expression: A cancer registry-linked insurance claims study. Journal Of Clinical Oncology 2022, 40: 399-399. DOI: 10.1200/jco.2022.40.28_suppl.399.Peer-Reviewed Original ResearchMetastatic breast cancerAnti-HER2 therapyHER2-low expressionMBC patientsEmergency departmentIHC 0Endocrine monotherapyEndocrine therapyTreatment patternsInfusion visitsCDK4/6 inhibitorsHER2 expressionBreast cancerDe novo metastatic breast cancerRetrospective population-based cohort studyNovo metastatic breast cancerBreast cancer-specific mortalityCancer-specific mortality ratesPopulation-based cohort studyHealth care resource useState cancer registry dataHormone receptorsCancer-specific mortalityHealthcare resource utilizationHormone receptor statusLong-Term Survival and Causes of Death After Diagnoses of Common Cancers in 3 Cohorts of U.S. Health Professionals
Cheng E, Lee DH, Tamimi RM, Hankinson SE, Willett WC, Giovannucci EL, Eliassen AH, Stampfer MJ, Mucci LA, Fuchs CS, Spiegelman D. Long-Term Survival and Causes of Death After Diagnoses of Common Cancers in 3 Cohorts of U.S. Health Professionals. JNCI Cancer Spectrum 2022, 6: pkac021-. PMID: 35603853, PMCID: PMC8973409, DOI: 10.1093/jncics/pkac021.Peer-Reviewed Original ResearchConceptsCancer-specific mortalityHealth Study IIUterine corpusCause of deathCommon cancerThyroid cancerPrimary cancerCancer survivorsLung cancerCumulative mortalityHealth StudyColorectal cancer-specific mortalityLong-term overall survivalNurses' Health Study IICancer-specific mortality ratesU.S. health professionalsHealth Professionals FollowNurses' Health StudyMale cancer survivorsFemale cancer survivorsProfessionals FollowMost patientsOverall survivalExcess riskUrinary bladder
2020
Long-term cancer survival in cohorts of U.S. health professionals.
Cheng E, Lee D, Tamimi R, Hankinson S, Willett W, Giovannucci E, Eliassen H, Tworoger S, Meir S, Mucci L, Fuchs C, Spiegelman D. Long-term cancer survival in cohorts of U.S. health professionals. Journal Of Clinical Oncology 2020, 38: 12075-12075. DOI: 10.1200/jco.2020.38.15_suppl.12075.Peer-Reviewed Original ResearchCancer-specific mortality ratesMortality rateCancer patientsOvarian cancerMajor cancersLong-term cancer survivalCorpus cancer patientsU.S. health professionalsHealth Professionals FollowUterine corpus cancerKaplan-Meier curvesMortality 10 yearsCause-specific mortality ratesCause of deathCumulative mortality rateLong-term survivalNHS IICorpus cancerIndex cancerProfessionals FollowUterine corpusColorectal cancerCancer survivalBreast cancerHealth StudyStatin and Cancer Mortality and Survival: An Umbrella Systematic Review and Meta-Analysis
Jeong G, Lee K, Kim J, Eisenhut M, Kronbichler A, van der Vliet H, Shin J, Gamerith G. Statin and Cancer Mortality and Survival: An Umbrella Systematic Review and Meta-Analysis. Journal Of Clinical Medicine 2020, 9: 326. PMID: 31979352, PMCID: PMC7074262, DOI: 10.3390/jcm9020326.Peer-Reviewed Original ResearchCancer mortalityLevel of evidenceUmbrella review of meta-analysesMeta-analyses of observational studiesMeta-analysesReview of meta-analysesComprehensive umbrella reviewReduce cancer mortalityStatin useAssociated with reduced all-cause mortalityStrength of evidenceAll-Cause MortalityWeak level of evidencePreventive effect of statinsCancer-specific mortality ratesEffect sizeConfidence intervalsRelevant articlesColorectal cancerObservational studyMortality ratePubMed databasePotential biasAssociationMortality
2019
Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes
Moschini M, Zamboni S, Soria F, Mathieu R, Xylinas E, Tan W, Kelly J, Simone G, Meraney A, Krishna S, Konety B, Mattei A, Baumeister P, Mordasini L, Montorsi F, Briganti A, Gallina A, Stabile A, Sanchez-Salas R, Cathelineau X, Rink M, Necchi A, Karakiewicz P, Rouprêt M, Koupparis A, Kassouf W, Scherr D, Ploussard G, Boorjian S, Lotan Y, Sooriakumaran P, Shariat S. Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. Journal Of Clinical Medicine 2019, 8: 1192. PMID: 31395826, PMCID: PMC6722857, DOI: 10.3390/jcm8081192.Peer-Reviewed Original ResearchRobot-assisted radical cystectomyOpen radical cystectomyCancer-specific mortalitySurvival outcomesRadical cystectomyPropensity score matchingBladder cancerPatients treated with robot-assisted radical cystectomyAssociation of surgical techniqueLong-term survival outcomesCancer-specific mortality ratesMultivariate Cox regression analysisMultivariate competing risk analysisOpen radical cystectomy patientsRobot-assisted radical cystectomy patientsBilateral pelvic lymphadenectomyCompare survival outcomesMedian Follow-UpUrothelial bladder cancerScore matchingCox regression analysisPropensity-matched cohortCompeting Risk AnalysisPelvic lymphadenectomyMulticentre cohortConservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database
Mahal A, Butler S, Franco I, Muralidhar V, Larios D, Pike L, Zhao S, Sanford N, Dess R, Feng F, D’Amico A, Spratt D, Yu J, Nguyen P, Rebbeck T, Mahal B. Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer 2019, 125: 3338-3346. PMID: 31251398, DOI: 10.1002/cncr.32332.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerPositive biopsy coresShort-term outcomesBiopsy coresProstate cancerManagement of low-risk prostate cancerOlder patientsProstate cancer-specific mortality ratesConservative managementProstate cancer-specific mortalityCancer-specific mortality ratesActive surveillance/watchful waitingRate of conservative managementOlder menCancer-specific mortalityShort-term safetyQuality-of-life implicationsDefinitive treatmentYounger patientsOverall mortalityPatientsMortality rateProstateNational databaseCancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply